Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Intangibles (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Intangibles for 15 consecutive years, with $19.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Intangibles rose 670.03% to $19.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $19.8 million, a 670.03% increase, with the full-year FY2024 number at $19.8 million, up 670.03% from a year prior.
  • Intangibles was $19.8 million for Q4 2024 at Anika Therapeutics, up from $3.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $118.9 million in Q2 2020 to a low of $2.6 million in Q4 2023.
  • A 5-year average of $74.8 million and a median of $90.6 million in 2020 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: skyrocketed 1331.52% in 2020, then crashed 97.7% in 2023.
  • Anika Therapeutics' Intangibles stood at $91.2 million in 2020, then decreased by 9.63% to $82.4 million in 2021, then soared by 36.12% to $112.1 million in 2022, then plummeted by 97.7% to $2.6 million in 2023, then skyrocketed by 670.03% to $19.8 million in 2024.
  • Per Business Quant, the three most recent readings for ANIK's Intangibles are $19.8 million (Q4 2024), $3.1 million (Q3 2024), and $4.0 million (Q2 2024).